CN112426436A - Endometrium lotion and its application in treating endometritis - Google Patents
Endometrium lotion and its application in treating endometritis Download PDFInfo
- Publication number
- CN112426436A CN112426436A CN202011338569.0A CN202011338569A CN112426436A CN 112426436 A CN112426436 A CN 112426436A CN 202011338569 A CN202011338569 A CN 202011338569A CN 112426436 A CN112426436 A CN 112426436A
- Authority
- CN
- China
- Prior art keywords
- endometritis
- lotion
- uterus
- endometrium
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000004145 Endometritis Diseases 0.000 title claims abstract description 31
- 239000006210 lotion Substances 0.000 title abstract description 19
- 210000004696 endometrium Anatomy 0.000 title abstract description 8
- 210000004291 uterus Anatomy 0.000 claims abstract description 24
- 241001465754 Metazoa Species 0.000 claims abstract description 14
- 238000005406 washing Methods 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 10
- 239000002504 physiological saline solution Substances 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 8
- 230000002357 endometrial effect Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 10
- 241000588724 Escherichia coli Species 0.000 abstract description 3
- 238000011010 flushing procedure Methods 0.000 abstract description 2
- 241000283690 Bos taurus Species 0.000 description 24
- 230000002757 inflammatory effect Effects 0.000 description 10
- 230000028327 secretion Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000012173 estrus Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000009989 contractile response Effects 0.000 description 2
- 210000004246 corpus luteum Anatomy 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000009933 reproductive health Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Urology & Nephrology (AREA)
Abstract
The invention discloses an endometrium lotion and application thereof in treating endometritis, which is a normal saline lotion obtained by flushing the uterus of healthy animals. The endometritis washing liquid is injected into the uterus with endometritis, and the cure rate of the mouse escherichia coli endometritis model reaches 70%. Clinical tests show that the effective rate of the cow endometritis is 70 percent, and the cure rate is 60 percent.
Description
Technical Field
The invention relates to the field of animal medicine, in particular to a endometrium washing lotion and application thereof in treating endometritis.
Background
The uterus has been considered sterile for many years. However, since the middle of the 80's in the 20 th century, some studies found that bacteria were present in the uterus after the bacterial culture analysis of endometrial samples, and particularly, in recent years, the research and analysis of endometrial samples by a high throughput sequencing method also revealed that bacteria were present in the endometrium, suggesting possible colonization of bacteria in the uterus. Poor reproductive health outcomes are often associated with colonization of intrauterine bacteria, including chorionitis, pelvic inflammation, endometritis, and the like.
Endometritis is a common obstetrical disease caused by bacterial infection of animals after delivery, is frequently generated in cows, sows, dogs and the like, and has great harm to the reproductive performance of the animals. When the sick livestock suffer from endometritis, factors such as inflammatory products, bacterial toxins and the like act on the uterus, on one hand, normal physiological functions of the endometrium are influenced, and cycle disorder is caused; on the other hand, the vitality of the input sperms is directly influenced, and the implantation of the fertilized eggs and the embryos is blocked, so that the repeated infertility is caused, and some diseases of other reproductive systems can be secondary to cause the lifetime infertility.
At present, methods for treating animal endometritis include uterine perfusion antibiotic, systemic antibiotic therapy, biological method, hormone therapy, Chinese medicinal preparation method, etc., and the commonly used method is uterine perfusion antibiotic or hormone therapy. However, with the application of a large amount of antibacterial drugs, drug-resistant strains are continuously increased, and the application of the antibacterial drugs, hormones and the like is inevitable or drug residues occur, so that harm is indirectly brought to human health. The traditional Chinese medicine preparation has complex prescription, inconvenient operation, large dosage and slow effect; therefore, the problem to be solved urgently is to provide a medicament which has a good effect of treating the animal endometritis, small side effect and low cost.
Disclosure of Invention
The invention aims to solve the problems and provides an endometrial washing lotion and application thereof in treating endometritis.
An endometrial wash, which is a wash obtained by washing the uterus of a healthy animal;
the washing liquid is physiological saline washing liquid;
the healthy animals are unmated sexually mature animals.
The application of the endometrium lotion in preparing the medicine for treating endometritis is disclosed.
The invention provides an endometrium lotion and application thereof in treating endometritis, which is a normal saline lotion obtained by flushing the uterus of healthy animals. The endometritis washing liquid is injected into the uterus with endometritis, and the cure rate of the mouse escherichia coli endometritis model reaches 70%. Clinical tests show that the effective rate of the cow endometritis is 70 percent, and the cure rate is 60 percent.
Drawings
FIG. 1 ELISA test the effect of physiological saline wash on three different cytokines;
FIG. 2 fluorescent quantitation of the effect of physiological saline wash on three different cytokines.
Detailed Description
EXAMPLE 1 treatment of endometritis mice with physiological saline solution
1. Preparation of physiological saline lotion
Selecting a healthy female virginator mouse (SPF grade ICR mouse) with the age of 8-10 weeks as a healthy donor, injecting 50 mu L of physiological saline into the uterus of the mouse under the aseptic condition, staying for 2 minutes, and then withdrawing 30 mu L of liquid from the uterus to obtain the healthy mouse physiological saline washing liquid. The obtained physiological saline solution was stored at 4 ℃.
2. Clinical trial
1) Animal model
Taking the ICR of SPF grade to be small20 mice, each mouse perfused into uterus to a concentration of 1.0X 101025 mu L of CFU/mL escherichia coli, and after 24 hours, the establishment of a mouse endometritis model is successful.
2) Grouping and administration of drugs
Mice were randomly divided into two groups of 10 mice each, one group served as control group and one group served as treatment group. The treatment group uses the normal saline lotion prepared by the method every day, and uses an indwelling needle to perfuse 25 mu L of healthy bacteria liquid into the uterus, and the control group perfuses 25 mu L of normal saline into the uterus, once a day, and 5 days continuously as a treatment course.
3) Therapeutic effects
The experimental results are shown in fig. 1 and fig. 2, the cure rate of the normal saline control group is 0%, the cure rate of the normal saline lotion treatment group reaches 70%, and the experimental results are significantly different from the control group. The physiological saline lotion has obvious effect of treating the endometritis of the mouse.
EXAMPLE 2 treatment of endometritis in cows with physiological saline solution
1. Laboratory animal
20 sexually mature, unmatched and non-physiological cows with similar ages and body condition characteristics are selected from a certain cow factory in Changchun city, Jilin province and are diagnosed as follows: 1) whether the inflammatory secretion is discharged or not is checked, the inflammatory secretion or the trace (cow tail, nojiri part, and joints with filth and scab) left after the inflammatory secretion is discharged is seen during the check, and the clinical endometritis can be preliminarily determined; 2) rectal examination, which is to examine the position of the uterus, the shape of uterine horn, the size, the texture and the contractile response of the uterus, whether the ovary has a corpus luteum or not and further judge the severity of inflammation; 3) vaginal examination is performed by means of a prolapsus appliance, cervical opening, hyperemia and inflammatory secretion outflow can be seen, the amount and the character of pus are examined, and the nature and the severity of inflammation are determined. The selected 20 cattle have no inflammation symptoms, and the uterus is in a healthy state.
From a certain dairy farm in Changchun city, Jilin province, 40 cows with endometritis were selected and diagnosed as follows: 1) whether the inflammatory secretion is discharged or not is checked, the inflammatory secretion or the trace (cow tail, nojiri part, and joints with filth and scab) left after the inflammatory secretion is discharged is seen during the check, and the clinical endometritis can be preliminarily determined; 2) rectal examination, which is to examine the position of the uterus, the shape of uterine horn, the size, the texture and the contractile response of the uterus, whether the ovary has a corpus luteum or not and further judge the severity of inflammation; 3) vaginal examination is performed by means of a prolapsus appliance, cervical opening, hyperemia and inflammatory secretion outflow can be seen, the amount and the character of pus are examined, and the nature and the severity of inflammation are determined. The uterine horn of 40 dairy cows selected by the test is obviously thickened, the external opening of the cervix is swollen, and all the inflammatory secretion is discharged, and the dairy cows belong to moderate and severe endometritis.
2. Preparation of physiological saline lotion
Selecting the healthy cow as a healthy donor, firstly disinfecting the instruments contacting the cow body and the perineum of the cow by using 0.1% benzalkonium bromide solution, secondly using a rectum to hold semen deposition method, injecting 300mL of sterile normal saline into the uterus of the cow by using a semen deposition device, staying for 2 minutes, and then withdrawing 150mL of liquid from the uterus to obtain the healthy cow normal saline lotion. The physiological saline lotion obtained by 20 selected cows is completely mixed according to the method and stored at 4 ℃ for later use.
3. Grouping and administration of drugs
Grouping: the sick cows were randomly divided into a control group and a treatment group, and each group had 20 cows.
The administration method comprises the following steps: the treatment group was administered 100 mL of the physiological saline solution prepared as described above into uterus daily using a spermatic apparatus. The control group was infused with physiological saline 1 time per day for 5 consecutive days as a treatment course. The treatment results were examined after 1 treatment course.
4. Determination of therapeutic effect
It is divided into curative, improving and ineffective. And (3) curing: clinical symptoms disappear, normal oestrus is recovered, and mucus is normal during oestrus; improving, clinical symptoms disappear, and estrus is recovered, but mucus is abnormal during estrus; no effect, no obvious improvement of clinical symptoms and uterine functions.
5. Therapeutic effects
The treatment results are shown in table 1, the cure rate of the normal saline control group is 0%, the cure rate of the normal saline lotion treatment group is 60%, the effective rate is 70%, and the treatment results are significantly different from the control group. The physiological saline lotion has obvious effect of treating the bovine endometritis.
In the actual production, the beef cattle or beef cattle uterus lotion to be slaughtered can be adopted to treat cow or cattle endometritis.
Claims (4)
1. An endometrial washing fluid characterized in that: it is a wash obtained by rinsing the uterus of healthy animals.
2. An endometrial wash as claimed in claim 1 wherein: the washing liquid is physiological saline washing liquid.
3. An endometrial wash as claimed in claim 1 or 2 wherein: the healthy animals are unmated sexually mature animals.
4. Use of an endometrial wash as claimed in claim 1 for the manufacture of a medicament for the treatment of endometritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011338569.0A CN112426436A (en) | 2020-11-25 | 2020-11-25 | Endometrium lotion and its application in treating endometritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011338569.0A CN112426436A (en) | 2020-11-25 | 2020-11-25 | Endometrium lotion and its application in treating endometritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112426436A true CN112426436A (en) | 2021-03-02 |
Family
ID=74697712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011338569.0A Pending CN112426436A (en) | 2020-11-25 | 2020-11-25 | Endometrium lotion and its application in treating endometritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112426436A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120052093A1 (en) * | 2009-04-23 | 2012-03-01 | Cornell University | Compositions and methods for preventing and treating uterine disease |
| US20140134144A1 (en) * | 2012-07-13 | 2014-05-15 | Burim Ametaj | Use of probiotic bacterial strains as a prophylactic tool against uterine infections in pregnant female ruminants |
| CN104997571A (en) * | 2015-07-13 | 2015-10-28 | 付静涛 | Method for improving estrus rate of cows |
| CN105287644A (en) * | 2015-09-14 | 2016-02-03 | 吉林农业大学 | Probiotics composition living bacteria preparation for treating subendometritis of dairy cow |
| CN106106364A (en) * | 2016-07-29 | 2016-11-16 | 董标 | A kind of cultural method improving sow reproductive performance |
| CN110946878A (en) * | 2019-11-27 | 2020-04-03 | 沣潮医药科技（上海）有限公司 | Application of uterine cavity fluid source exosome in preparation of medicine and adjuvant therapy agent for treating infertility related diseases |
| CN114717150A (en) * | 2022-04-20 | 2022-07-08 | 河北农业大学 | Lactobacillus plantarum CRS33 and application thereof |
-
2020
- 2020-11-25 CN CN202011338569.0A patent/CN112426436A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120052093A1 (en) * | 2009-04-23 | 2012-03-01 | Cornell University | Compositions and methods for preventing and treating uterine disease |
| US20140134144A1 (en) * | 2012-07-13 | 2014-05-15 | Burim Ametaj | Use of probiotic bacterial strains as a prophylactic tool against uterine infections in pregnant female ruminants |
| CN104997571A (en) * | 2015-07-13 | 2015-10-28 | 付静涛 | Method for improving estrus rate of cows |
| CN105287644A (en) * | 2015-09-14 | 2016-02-03 | 吉林农业大学 | Probiotics composition living bacteria preparation for treating subendometritis of dairy cow |
| CN106106364A (en) * | 2016-07-29 | 2016-11-16 | 董标 | A kind of cultural method improving sow reproductive performance |
| CN110946878A (en) * | 2019-11-27 | 2020-04-03 | 沣潮医药科技（上海）有限公司 | Application of uterine cavity fluid source exosome in preparation of medicine and adjuvant therapy agent for treating infertility related diseases |
| CN114717150A (en) * | 2022-04-20 | 2022-07-08 | 河北农业大学 | Lactobacillus plantarum CRS33 and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| NEREA M. MOLINA,等: "New Opportunities for Endometrial Health by Modifying Uterine Microbial Composition:Present or Future?", 《BIOMOLECULES》 * |
| 孙凯鑫: "子宫菌群移植对小鼠子宫内膜炎的治疗作用", 《中国优秀硕士学位论文全文数据库 农业科技辑》 * |
| 杨增，等: "约氏乳杆菌对ＬＰＳ诱导的奶牛子宫内膜上皮细胞炎症反应的影响", 《中国兽医学报》 * |
| 桑梦琪: "奶牛生殖道益生性乳酸菌分离鉴定及其复合制剂的研究", 《中国优秀硕士学位论文全文数据库 农业科技辑》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Garcia‐Ispierto et al. | Reproductive performance of anoestrous high‐producing dairy cows improved by adding equine chorionic gonadotrophin to a progesterone‐based oestrous synchronizing protocol | |
| CN100493600C (en) | Pharmaceutical composition for preventing and curing endometritis and retained afterbirth disease of milk cow | |
| Samardžija et al. | Intrauterine ozone treatment of puerperal disorders in domestic ruminants: a review | |
| CN103316312B (en) | A kind of tonification clearing heat in the pericardium mixture and preparation technology thereof | |
| CN1255135C (en) | Chinese traditional medicine perfusate for preventing and treating female livestock barrenness | |
| Palomares et al. | Oxytocin treatment immediately after calving does not reduce the incidence of retained fetal membranes or improve reproductive performance in crossbred Zebu cows | |
| CN112426436A (en) | Endometrium lotion and its application in treating endometritis | |
| CN108451896B (en) | Device for controlling development of animal follicles and preventing and treating genital tract inflammation and preparation method | |
| CN105188721B (en) | Tungsten（VI）Salt is used for the purposes for treating the female sterile disease of non-diabetic mammal | |
| CN107427555A (en) | Healthy reproduction and suppress the composition and method of hyperketonemia using IL 8 to increase the output of milk and improve in mammal | |
| Sharma et al. | Causes and therapeutic management of infertility in abandoned cows of Himachal Pradesh | |
| CN110507736B (en) | A Chinese medicinal perfusate for treating endometritis of female animal, and its preparation method | |
| Cui et al. | Prophylactic strategy with herbal remedy to reduce puerperal metritis risk in dairy cows: A randomized clinical trial | |
| CN1268355C (en) | Traditional Chinese medicine for treating cow endo metritis | |
| CN104825478B (en) | A kind of preparation method for being used to treat the pharmaceutical composition and its perfusion liquid of cow endometritis | |
| CN104288162B (en) | A kind of milch cow doxycycline hydrochloride uterus injectant and preparation method thereof | |
| Modric et al. | Hormonal and antimicrobial therapy in theriogenology practice: Currently approved drugs in the USA and possible future directions | |
| CN111000653B (en) | Device and method for controlling follicular development of equine animals and preventing and treating genital tract inflammation | |
| Rahim et al. | Use of vitamin E and selenium injections as supportive treatment of retained placenta in dairy cattle | |
| CN1981826A (en) | Uterus perfusion for treating bull metritis | |
| RU2392928C2 (en) | Method of endometritis treatment and prevention in cows | |
| CN1463699A (en) | A composition for treating animal endometritis | |
| Gupta et al. | Evaluation of intra-uterine lugol's iodine therapy and double PGF2α shot for treatment of subclinical endometritis in dairy cattle. | |
| Trundell | Equine reproduction: Seasonality, endometritis, and twinning in the mare | |
| Amirov et al. | Uterus Diseases In Cows-Endometritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210302 |
|
| RJ01 | Rejection of invention patent application after publication |